Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Temozolomide in Recurrent Glioblastoma
NCT03643549Phase 2Recruiting
- Sponsor
- Haukeland University Hospital
- Start
- Aug 2018
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in glioblastoma (GBM), sponsored by Haukeland University Hospital. Started Aug 2018; status: recruiting.
02
Drugs
bortezomib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03643549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03643549.